Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.
Tags: Allergan Inc
Pfizer chief Ian Read's pay falls 23%
Pfizer said that net compensation of chief executive officer Ian Read declined 23% in 2015 driven by a drop in stock awards. The chief's net compensation amounted to $18 million in 2015.
Valeant to drop deal-making in near term to cut debt, boost stock
Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.
Valeant ready to raise Allergan bid to at least $200/share
Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.
Actavis plans new merger approach for Allergan - sources
Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.
Latest News
Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.
1
